IMR Press / FBL / Volume 17 / Issue 7 / DOI: 10.2741/4075

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


The role of melatonin treatment in chronic kidney disease

Show Less
1 Department of Hospital Pharmacy, Meander Medical Center, Amersfoort, The Netherlands
2 Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, The Netherlands
3 Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands
4 Department of Nephrology, VU University Medical Center, Amsterdam, The Netherlands
5 Department of Internal Medicine, Meander Medical Center, Amersfoort, The Netherlands
Front. Biosci. (Landmark Ed) 2012, 17(7), 2644–2656;
Published: 1 June 2012

The pineal hormone melatonin plays a major role in circadian sleep-wake rhythm. Patients with Chronic Kidney Disease (CKD), especially those who are on hemodialysis, frequently suffer from sleep disturbances. In this review an overview is given of the classification of stages of chronic kidney disease, followed by a presentation of the circadian rhythm disorders in renal disease involving sleep disturbances in relation to melatonin deficiency. The therapeutic benefit of melatonin treatment in sleep disorders related to chronic kidney disease including the controlled trials solving this topic, is described. Furthermore, the beneficial effect of melatonin on blood pressure alterations in CKD states and the protection of melatonin in oxidative stress and inflammation in renal disorders are explored. Finally a hypothetic model is described for the relation between circadian rhythm disorders and CKD.

Back to top